Comparison of cisplatin plus vindesine with cisplatin plus mitomycin C for treatment of advanced non-small-cell lung cancer. The Eastern Shikoku Lung Cancer Chemotherapy Group.
Seventy-six patients with advanced non-small-cell lung cancer were randomly allocated to two groups and treated with cisplatin (CDDP; 80 mg/m2 on day 1) plus either vindesine (VDS; 3 mg/m2 on days 1 and 8) or mitomycin C (MMC; 8 mg/m2 on days 1 and 8) every 3-4 weeks. The objective response rates were 26% (10/38) for CDDP plus VDS and 32% (11/34) for CDDP plus MMC; the corresponding response rates in patients with adenocarcinoma were 7% (1/14) and 43% (6/14), respectively. The median survival times of patients treated with CDDP plus VDS and CDDP plus MMC were 33 and 30 weeks, respectively, the difference in survival times in the two groups not being significant. There was no significant difference in toxic effects in the two groups except that alopecia and leukopenia were more frequent in patients treated with CDDP plus VDS.
Shimizu
E
E
3rd Department of Internal Medicine, Tokushima University School of Medicine, Japan.
Ogura
T
T
Sone
S
S
Nakayama
T
T
Doi
H
H
Takishita
Y
Y
Bando
H
H
Kobayashi
M
M
Kimura
K
K
Sasaki
H
H
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D016019:Survival Analysis; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
D016685:Mitomycin; D002945:Cisplatin; D014751:Vindesine